Renin-Inhibitors Market in India, Industry Outlook and Forecast 2024-2030

Renin inhibitors are one of four classes of compounds that affect the renin-angiotensin-aldosterone system. Renin inhibitors produce vasodilation by inhibiting the activity of renin, which is responsible for stimulating angiotensin II formation. Renin is a proteolytic enzyme that is released by the kidneys in response to sympathetic activation, hypotension, and decreased sodium delivery to the distal renal tubule. Aliskiren (INN) (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.

This report contains market size and forecasts of Renin-Inhibitors in India, highlights the following information:

Sales of Renin-Inhibitors in India: Value 2019 VS 2023 VS 2030, ($ millions)

Sales of Renin-Inhibitors in India: Volume 2019 VS 2023 VS 2030, (K Tablet)

Sales of Renin-Inhibitors in India: Revenue Market Share by Company, 2019-2024

Sales of Renin-Inhibitors in India: Volume Market Share by Company, 2019-2024

India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.

India is a market full of opportunities, and the demand for Renin-Inhibitors will continue to grow rapidly in the future.

The global Renin-Inhibitors market size was valued at 91 million in 2023 and is forecast to a readjusted size of US$ 145 million by 2030, with a CAGR of 6.8% during the forecast period 2024-2030.While the India Renin-Inhibitors market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. India will account for % percent of Renin-Inhibitors's global value in 2030, from % in 2023.

Our research team has surveyed the Renin-Inhibitors manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, Value, demand, price change, product matrix, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

India Renin-Inhibitors Market, By Type, 2019-2024, 2025-2030 ($ Millions) & (K Tablet)

India Renin-Inhibitors Market Segment Percentages, By Type, 2023 (%)

150mg/Tablet

300mg/Tablet

India Renin-Inhibitors Market, By Application, 2019-2024, 2025-2030 ($ Millions) & (K Tablet)

India Renin-Inhibitors Market Segment Percentages, By Application, 2023 (%)

Age below 45

Age 45-55

Age 55-65

Age above 65

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Renin-Inhibitors revenues in India market, 2019-2024 (Estimated), ($ millions)

Key companies Renin-Inhibitors sales in India market, 2019-2024 (Estimated), (K Tablet)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

Noden Pharma